A post-hoc analysis of the MIRRA trial of mepolizumab assessed the corticosteroid-sparing effect of mepolizumab in patients with EGPA.
Is omalizumab equally efficacious in treating allergic asthma among children from varying racial/ethnic backgrounds?
How effective are house dust mite sublingual immunotherapy tablets in controlling allergic rhinitis/conjunctivitis in adults and adolescents?
A recent study demonstrates an approach for evaluating and managing patients with adverse events following immunization with the COVID-19 vaccine.
Research presented at ACAAI 2021 assessed associations between IBD, eosinophilic esophagitis, esophageal eosinophilia, and atopic disease in children.
How does oral immunotherapy succeed in stopping individuals with peanut allergies from experiencing an allergic reaction to peanuts?
CHRONICLE investigators reported results of a patient survey on common asthma triggers at ACAAI 2021.
The SINUS-24/52 trial evaluated dupilumab’s impact on CRSwNP and comorbid asthma, looking at baseline asthma characteristics.
In CHRONICLE, researchers examined associations between exacerbations and initiation of biologic therapy in patients with uncontrolled severe asthma.
Asthma control as measured by AIRQ may predict 12-month HRQoL, according to research reported at the 2021 ACAAI Annual Scientific Meeting.
A post-hoc analysis of LAVOLTA I and II trials assessed effectiveness of lebrikizumab in patients with uncontrolled asthma and high baseline eosinophils.
A retrospective review presented at ACAAI 2021 assessed median cumulative corticosteroid exposure before and after initiation of biologic therapy in AERD.
A post hoc analysis of the QUEST trial assessed clinical remission in patients with moderate-to-severe asthma after 24 and 52 weeks of dupilumab treatment.
Can clinicians identify children who are at risk of developing a persistent wheeze?
CHRONICLE trial findings offer a glimpse of the real-world outcomes of patients using benralizumab for severe asthma over a years’ time.